Date: 2016-04-16
Type of information: Research agreement
Compound: first-in-class bispecific small molecule immuno-oncology therapies
Company: Evotec (Germany) Exscientia (UK)
Therapeutic area: Cancer - Oncology
Type agreement: research - R&D - collaboration
Action mechanism: bispecific molecule.
Disease:
Details: • On April 26, 2016, Evotec and Exscientia announced a research collaboration with the objective to discover and develop first-in-class bispecific small molecule immuno-oncology therapies. Ex scientia will contribute its unique algorithmic design platform while Evotec, mainly through its Toulouse site, will be responsible for medicinal chemistry, in vitro and in vivo pharmacology as well as development capabilities and expertise. The initial focus will be cancer-related adenosine targets which are increasingly recognised to play important roles in immuno-oncology. Combining adenosine-based mechanisms with related targets holds great promise in boosting efficacy and addressing larger patient populations through a single small molecule drug.
Financial terms: No financial details were disclosed.
Latest news:
